Cite
Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data.
MLA
Uemura, Koichi, et al. “Enfortumab Vedotin Prolongs Overall Survival in Metastatic Urothelial Carcinoma Following Pembrolizumab Therapy in Real‐world Data.” International Journal of Urology, vol. 31, no. 6, June 2024, pp. 678–84. EBSCOhost, https://doi.org/10.1111/iju.15437.
APA
Uemura, K., Ito, H., Jikuya, R., Kondo, T., Tatenuma, T., Kawahara, T., Ito, Y., Komeya, M., Muraoka, K., Hasumi, H., Uemura, H., & Makiyama, K. (2024). Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data. International Journal of Urology, 31(6), 678–684. https://doi.org/10.1111/iju.15437
Chicago
Uemura, Koichi, Hiroki Ito, Ryosuke Jikuya, Takuya Kondo, Tomoyuki Tatenuma, Takashi Kawahara, Yusuke Ito, et al. 2024. “Enfortumab Vedotin Prolongs Overall Survival in Metastatic Urothelial Carcinoma Following Pembrolizumab Therapy in Real‐world Data.” International Journal of Urology 31 (6): 678–84. doi:10.1111/iju.15437.